Abstract CT226: ADELA: A double-blind, placebo-controlled, randomized phase 3 trial of elacestrant (Ela) + everolimus (EVE) versus elacestrant + placebo in ER+/HER2- advanced breast cancer (aBC) patients with ESR1-mutated tumors progressing on endocrine therapy (ET) + CDK4/6i
Year: 2026
Type: conference-abstract
Source: Cancer Research
Authors: Antonio Llombart-Cussac, José Manuel Pérez-García, Elena Lopez-Miranda, Cristina Saavedra, Vicente Carañana, Isabel Blancas, Carmen Hinojo-González, Alfonso Cortes-Salgado, Elena Galve, Rui Rui Zhang, Miguel Sampayo-Cordero, Daniel Alcalá-López, Juliana Carvalho-Santos, Olga Boix, Ana Garrido, Carlos H. Barrios, Giuseppe Curigliano, Rupert Bartsch, Anne Claire Bessard, Tomer Wasserman, Javier Cortés
Institutions: MedSIR (Spain), Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, Hospital Arnau de Vilanova, Marqués de Valdecilla University Hospital, Instituto de Investigación Marqués de Valdecilla, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Universitario Ramón y Cajal, Hospital de Basurto, Latin American Cooperative Oncology Group (LACOG), European Institute of Oncology, Medical University of Vienna, UniCancer Group
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7154735291
Cites:
Cited by:
Related to: